Human growth hormone crystals and methods for preparing them
The present invention relates to stable, extended release crystals of human growth hormone or a human growth hormone derivative and compositions or formulations comprising such crystals. The invention further provides methods for producing those crystals and compositions. The invention further provides methods for treatment of an individual having disorders associated with human growth hormone deficiency or which are ameliorated by treatment with human growth hormone using those crystals and compositions or formulations.
1. A composition comprising a crystal of human growth hormone (hGH), and polyarginine wherein said crystal of hGH is crystallized from a solution free of polyarginine and is soaked in polyarginine, and wherein said crystal of hGH comprises at least one cation and hGH which is selected from the group consisting of:
(a) the 191 amino acid sequence of native hGH (SEQ ID NO:1); and
(b) the 192 amino acid sequence of somatrem consisting of said 191 amino acid sequence of native hGH (SEQ ID NO:1) and an additional N-terminal methionine,
and wherein said hGH is present in a hGH:polyarginine ratio of 5:1 (w/w) to 40:1 (w/w).
2. The composition according to claim 1 , wherein said cation is a calcium ion.
3. The composition according to claim 1 , wherein said cation is a sodium ion.
4. A composition comprising a crystal of human growth hormone (hGH), and polyarginine wherein said crystal of hGH is crystallized from a solution free of polyarginine and is soaked in polyarginine, and wherein said crystal of hGH comprises at least one cation and hGH which is selected from the group consisting of:
(a) the 191 amino acid sequence of native hGH (SEQ ID NO:1); and
(b) the 192 amino acid sequence of somatrem consisting of said 191 amino acid sequence of native hGH (SEQ ID NO:1) and an additional N-terminal methionine; and
wherein said hGH is present in a hGH:polyarginine ratio of 5:1 (w/w) to 40:1 (w/w); and
wherein a single administration of said composition to a mammal provides an in vivo human growth hormone (hGH) serum concentration profile in said mammal having a T 90% value higher than that provided by a single administration of the same amount of soluble human growth hormone, and wherein T 90% is the time required to reach 90% of the total desired solubilized hGH level in a serum in vivo from the single administration hGH crystal has been achieved and wherein said higher T 90% represents slower in vivo dissolution rate.
5. The composition according to claim 4 , wherein said cation is a calcium ion.
6. The composition according to claim 4 , wherein said cation is a sodium ion.
7. A composition comprising a crystal of human growth hormone (hGH), and polyarginine wherein said crystal of hGH is crystallized from a solution free of polyarginine, and is soaked in polyarginine, and wherein said crystal of hGH comprises at least one cation and hGH which is selected from the group consisting of:
(a) the 191 amino acid sequence of native hGH (SEQ ID NO:1); and
(b) the 192 amino acid sequence of somatrem consisting of said 191 amino acid sequence of native hGH (SEQ ID NO:1) and an additional N-terminal methionine;
wherein a single administration of said composition to a mammal provides an in vivo insulin-like growth factor-I (IGF-1) serum elevation over baseline IGF-1 level in said mammal at similar levels compared to those provided by the same amount of soluble human growth hormone (hGH) administered in more than one administration; and
wherein said hGH is present in a hGH:polyarginine ratio of 5:1 (w/w) to 40:1 (w/w).
8. The composition according to claim 7 , wherein said cation is a calcium ion.
9. The composition according to claim 7 , wherein said cation is a sodium ion.
10. A composition comprising a crystal of human growth hormone (hGH), and polyarginine wherein said crystal of hGH is crystallized from a solution free of polyarginine, and is soaked in polyarginine, and wherein said crystal of hGH comprises at least one cation and hGH which is selected from the group consisting of
(a) the 191 amino acid sequence of native hGH (SEQ ID NO:1); and
(b) the 192 amino acid sequence of somatrem consisting of said 191 amino acid sequence of native hGH (SEQ ID NO:1) and an additional N-terminal methionine;
wherein a single administration of said composition has a bioavailability of at least 50% or more, as compared to that of an identical dose of soluble human growth hormone (hGH) delivered via the same administrative route, wherein said bioavailability is measured by area under curve (AUC) of total in vivo hGH serum concentration for said soluble hGH and said hGH crystal;
and wherein said hGH is present in a hGH:polyarginine ratio of 5:1 (w/w) to 40:1 (w/w).
11. The composition according to claim 4 or 7 , wherein said mammal is a human.
12. The composition according to claim 1 , 4 , 7 , or 10 , further comprising an additional excipient.
13. The composition according to claim 12 , wherein said additional excipient is selected from the group consisting of amino acid, a salt, an alcohol, a carbohydrate, a protein, a lipid, a surfactant, a polymer, a polyamino acid wherein said polyamino acid is not polyarginine, and mixtures thereof.
14. The composition according to claim 12 , wherein said additional excipient is selected from the group consisting of protamine, polyvinylalcohol, cyclodextrin, dextran, calcium gluconate, polyamino acid wherein said polyamino acid is not polyarginine, polyethylene glycol, a dendrimer, polyorthinine, polyethyleneimine, chitosan and mixtures thereof.
15. The composition according to claim 14 , wherein said additional excipient is selected from the group consisting of: protamine, polyethylene glycol and mixtures thereof.
16. The composition according to claim 12 , wherein the concentration of human growth hormone (hGH) in said composition is between 0.1 and 100 mg/ml.
17. The composition according to claim 1 , 4 , 7 or 10 , produced by:
(a) crystallizing the hGH with a cation, in a buffer with a pH between about 6 and 9, said buffer free of polyarginine; and then
(b) adding polyarginine to the crystal of hGH with a cation formed in step (a).
18. A pharmaceutical composition comprising the composition of claim 1 .
19. A pharmaceutical composition comprising the composition of claim 2 .
20. A pharmaceutical composition comprising the composition of claim 4 .
21. A pharmaceutical composition comprising the composition of claim 17 .
22. A pharmaceutical composition comprising the composition of claim 7 .
23. A pharmaceutical composition comprising the composition of claim 10 .